As AD Trials Come of Age, Will Cognitive Tests Follow Suit?
Showing that an experimental Alzheimer’s therapy delivers meaningful cognitive change is hard enough...
6401 RESULTS
Sort By:
Showing that an experimental Alzheimer’s therapy delivers meaningful cognitive change is hard enough...
Flagging mitochondria, the powerhouses of the cell, have been linked to general aging and also to a variety of neurodegenerative diseases...
The presence of small oligomeric protein assemblies with neurotoxic properties has become a common thread in several neurodegenerative diseases...
Experimental evidence and plain common sense tell us that neurons lose activity in Alzheimer disease...
At first glance, the pair of proteins that form the key pathological features of Alzheimer disease seem quite an odd couple...
Human memory is one of the last great biological mysteries...
Among the plethora of factors that might serve as useful biomarkers for AD, perhaps none draws as much scrutiny as plasma amyloid-β...
Recent work indicates that CSF BACE activity is significantly increased in people with AD...
Healthy aging relies on proper function of the transcription factor p53...
Hopping off the couch and into the gym helps both heart and mind, even in seniors at risk for dementia...
The hopes for treating AD by inhibiting the amyloid-producing enzyme β-secretase (BACE) rest largely on results obtained in mice...
Researchers report a new role for certain presenilin-1 mutations that cause early-onset familial Alzheimer disease (eFAD)...
Amyloid-β (Aβ) peptides in cerebrospinal fluid are among the few established molecular signs of impending Alzheimer disease...
While the media focuses on the next potential billion-dollar pharmaceutical treatment of AD, other investigators have been quietly cooking up alternative approaches...
Two anti-amyloid approaches—PBT2 and IVIg—came out with Phase 2 data at ICAD...